Product Images Galbriela

This is a list of various studies comparing the use of combined oral contraceptives (COC) among women, with different results and statistics presented in terms of odds ratio (OR), relative risk (RR), and hazard ratio (HR). The studies include NICHD Women’s Care Study, French E3N cohort Study, Shanghai Women's Health Study, Nurses’ Health Study II, and Oxford Family Planning Study. The results indicate different associations between COC use and certain health outcomes, although the details of the outcomes and implications are not clearly defined in the given text.*

This text provides information on the effectiveness of different forms of birth control methods in preventing pregnancies. It categorizes methods such as implants, injections, intrauterine devices, sterilization, birth control pills, skin patch, vaginal rings with hormones, condoms, diaphragm, no sex during fertile days, spermicide, withdrawal, and no birth control. The text indicates the varying effectiveness rates, ranging from fewer than 1 pregnancy per 100 women for highly effective methods to 85 or more pregnancies per 100 women for less effective methods.*

This text provides instructions on how to label a period tracker based on the start day of the menstrual cycle. It also includes information on a medication called Galbrela™ (Norethindrone and Ethinyl Estradiol Tablets) with Ferrous Fumarate Tablets and storage recommendations.*

This text describes a medication called Reonly Galbriela, which consists of chewable tablets containing a combination of norethindrone, ethinyl estradiol, and ferrous fumarate. The product aims to prevent pregnancy and each blister pack contains 24 dark yellow tablets with norethindrone and ethinyl estradiol and 4 brown tablets with ferrous fumarate. The medication does not protect against HIV/AIDS or other sexually transmitted diseases. Additionally, the packaging includes details about the tablet contents and instructions for use.*